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Highlights  
 Standard IV posaconazole doses may be inadequate for aspergillosis during 
hypalbuminaemia   
 Standard IV posaconazole doses are likely to be adequate for susceptible yeast 
infections  
 No supranormal posaconazole accumulation is anticipated in a patient undergoing 
CVVHDF 
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Abstract 
We present a pharmacokinetic case-study of intravenous posaconazole in a 49-years-old male 
patient with intra-abdominal sepsis and hypoalbuminemia receiving continuous venovenous 
hemodiafiltration. Concentration-time data following 300mg intravenous dose was analysed 
using a population pharmacokinetics approach. The 300mg intravenous dose appears 
adequate for the treatment of yeast infections; however, for treatment of invasive 
aspergillosis in isolated cases of critically ill patients with hypoalbuminemia, the current 
dosing may not achieve desired exposure although steady-state exposure data is needed.  
Key words: antifungal; intravenous posaconazole; renal replacement therapy; 
hypoalbuminaemia; pharmacokinetics   
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In the past few decades, numerous clinical studies have unequivocally demonstrated that 
pharmacokinetics (PK) of antimicrobials can be different in critically ill patients and a careful 
evaluation of all formulations intended for use in the critically ill should be performed in this 
specific patient population. For the newly introduced intravenous (IV) posaconazole 
preparation, only sparse data from critically ill patients exists.  In one study, the PK profile of 
oral posaconazole in surgical intensive care unit (ICU) patients was found to be different 
from hematology patients, with lower plasma concentrations, higher clearance and an 
increased volume of distribution (1). Given these changes could possibly be related to altered 
absorption from the gut, it remains unclear whether similar PK differences exist for the IV 
regimens. However, when considering the PK properties of posaconazole, for a number of 
reasons it may seem that the common PK changes anticipated in critically ill patients may be 
less significant after IV administration. Firstly, posaconazole is highly lipophilic and critical-
illness related changes in volume of distribution would be expected to be minimal (2, 3). 
Secondly, it undergoes limited hepatic metabolism and thus its PK is unlikely to be affected 
by hepatic dysfunction (4). Thirdly, the contribution of renal clearance is relatively low with 
77% of the drug being eliminated unchanged via biliary route (4, 5). Thus, changes in renal 
function including augmented renal clearance or acute kidney injury or the use of 
extracorporeal renal replacement therapy would have minimal effect on plasma exposure of 
posaconazole. Previous studies indeed reported that renal impairment or the use of dialysis 
have minimal impact on posaconazole PK (6, 7). However, given that posaconazole is highly 
protein bound (99%, (8)), its PK may be affected by hypoalbuminemia which is frequently 
observed in the critically ill.  
Here, we present a PK case study of posaconazole exposure after an IV administration in a 
critically ill patient with hypoalbuminemia and receiving continuous venovenous 
hemodiafiltration (CVVHDF).  
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A 49 year-old male patient (weight 120 kg, height 180 cm) with dialysis-dependent chronic 
kidney disease was admitted to hospital following a fall. Septic arthritis was initially 
suspected and the patient was investigated for knee pain and recurrent episodes of 
hypotension. The patient also complained an abdominal pain with generalized tenderness, 
which was treated as constipation in the general ward. However, the patient’s condition 
deteriorated into intra-abdominal sepsis and he was admitted to ICU after six days of 
treatment in the ward.  On ICU admission, the patient was febrile and hypotensive with sinus 
tachycardia, requiring inotropic support (noradrenaline) and mechanical (FiO2 35%, 
peripheral oxygen saturation 91%). Abdominal examination revealed a retracted non-
functioning stoma with absent bowel sounds and ischemic gut. The serum albumin 
concentration was 15 g/L. AST and ALT concentrations were 66 and 162 IU/mL 
respectively. The APACHE II score on admission was 33 and the SOFA score was 15. The 
patient was anuric and received CVVHDF using the PRISMAFLEX System (Baxter 
International Inc.) with an ST150 filter (AN 69 ST hollow fiber, an acrylonitrile and sodium 
methally sulfonate copolymer with surface area of 1.5 m
2
). The blood flow rate was 200 
mL/min, and the pre-dilution flow rate was 1000 mL/hr. Blood cultures were negative and the 
empiric antibiotic therapy on day 1 of ICU stay included vancomycin (1g twice daily, on day 
1 and 2) and meropenem (500 mg every 8 hours, on days 1 to 5). On day six, treatment was 
de-escalated to cefazolin alone (2 g IV). However, antibiotics were re-escalated the next day 
(day 7) with stat dose of 1.5 g vancomycin, cefepime 2 g twice daily (days 7 to 13), and 
caspofungin 70 mg once daily (days 7 to 12). On day 12, a stat dose of 850 mg daptomycin 
was given. Caspofungin was discontinued on day 12 and a stat dose of IV posaconazole was 
administered (300 mg infused over 90 minutes). Albumin level remained low ( < 15 g/L) on 
the day of posaconazole administration. The following day the patient was discharged from 
the ICU and the hospital (equivalent day 13 of ICU stay).  
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A day prior to discharge from the ICU, we conducted a PK evaluation of posaconazole after 
the single dose administration. Blood samples were collected from an arterial catheter 
immediately before the start of posaconazole infusion; during the infusion at 15 min, 45min, 
and 75 minutes; at the end of infusion at 90 minutes; and post-infusion at, 3h, 5h, 8h, 12h, 
18h, and 24h after the commencement of drug infusion. All samples were spun immediately 
after collection at 3000 rpm for 10 minutes and plasma was stored in - 80C freezer until drug 
assay. Total plasma concentrations of posaconazole were quantified using a validated 
UHPLC-MS/MS method (Shimadzu Nexera2 UHPLC, 8030+ MS/MS system, C18 XR-ODS 
III column). The method met all the requirements of the FDA guidance for bioanalysis (9).  
The concentration-time data (Figure 1) was modelled using the non-parametric adaptive grid 
approach in Pmetrics
®
 (a package within R®). A two-compartment model with linear 
elimination from central compartment best described the data (r
2
= 0.945). The estimated 
volume of the central compartment was 126.4 L and clearance (CL) was 16.8 L/h. This 
estimated CL for our patient was higher than a previously estimated value of 9.5 L/h in a case 
report of a patient receiving continuous venovenous hemodialysis, CVVH using non- 
compartmental methods (7). The increased CL in our patient could perhaps relate to the 
significant hypalbuminemia (albumin concentration was 15 g/L) which results in an increase 
in the free fraction of posaconazole in plasma. It is the free fraction that is cleared by renal 
replacement therapy/metabolism/biliary route, or distributed more extensively into tissue. 
Using the two-compartment structural PK model developed for our patient, dosing 
simulations (n=1000) were performed out to steady state (7 days) to explore the exposures 
likely to be achieved in the study patient from different IV dosing regimens. The simulated 
doses included 300 mg, 400 mg, 500mg, 750 mg, 1000mg and 2000mg, with each dose 
administered twice daily on day 1 followed by once daily thereafter (i.e. BID-day1-then-QD 
regimen). The predicted steady state exposure described as AUC0-24 is given in Table 1.   
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The exposures of posaconazole that maximise the likelihood of positive clinical outcome 
have not yet been well defined. In one clinical study of posaconazole use as a salvage therapy 
for invasive aspergillosis, an average steady state concentration of 1.5 mg/L that corresponds 
to approximately an AUC0-24  of 30 mg/L*h was associated with a 75% response rate (10).  
The currently approved 300 mg IV BID-day1-then-QD regimen appears unlikely to achieve  
this exposure in patients similar to the present study patient (Table 1). Further, higher IV 
doses of up to 500 mg given BID-day1-then-QD did not achieve this steady state exposure, 
and only doses ≥ 750 mg given BID-day1-then-QD would have achieved an AUC24h > 30 
mg/L*h for our patient and those with similar conditions. However, there remains uncertainty 
regarding the steady state concentrations of posaconazole associated with treatment succuss 
given inconsistent reports from previous studies. Another study, for example, recommended 
steady-state concentration therapeutic range of 0.5 to 2.5 mg/L (estimated from AUC0-24 
divided by 24 h) (11). From the dosing simulations, we observed the probability of achieving 
average steady state concentrations greater than 0.5 mg/L for the 300 mg BID-day1-then-QD 
regimen was 89%, and 100% for the rest of the simulated doses. Nevertheless, this target was 
mainly derived from a study investigating the prophylactic use of posaconazole (12) and 
patients with invasive fungal infection may require higher exposures (13). Indeed in the 
recent EUCAST rationale document for the clinical MIC breakpoints of posaconazole (14), 
experts recommended total trough concentrations should be greater than 1 mg/L in patients at 
risk of poor clinical outcomes such as those with profound neutropenia or severe sepsis. 
According to this recommendation, for other patients (e.g. those receiving prophylactic 
therapy), lower total concentration (> 0.7 mg/L) may be acceptable. Results of our dosing 
simulations (Table 1) show that IV doses exceeding the currently used 300 mg given BID-
day1-then-QD would be sufficient to achieve these concentrations in the present scenario.   
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Although steady-state trough or average concentrations may be good surrogates in the 
absence of defined PK/pharmacodynamic (PD) target for posaconazole, given that the 
exposure relative to the susceptibility of the pathogen is an important determinant of success 
of therapy (15), exposure normalized to the MIC of the pathogen should be utilized for more 
acute dosing. Preclinical studies have demonstrated that AUC/MIC ratio is the PK/PD index 
that best links posaconazole exposure to treatment outcomes, although the magnitude of this 
ratio has not been identified in clinical studies (15, 16). Based on animal model studies, total 
AUC/MIC ratios in the range of 167 to 178 were suggested to correlate with half-maximal 
antifungal effect against aspergillosis (17, 18). Considering an AUC/MIC ratio of 167, we 
determined the probability of target attainment (PTA) for various dosing regimens based on 
the posaconazole PK model for our patient (Figure 2). The 300 mg BID-day1-then-QD 
standard regimen achieved this target (PTA of 100 %) when considering the clinical MIC 
breakpoint of 0.06 mg/L for Candida species (14). However, at the recently defined 
EUCAST susceptibility breakpoint of 0.12mg/L for Aspergillus fumigatus (14), the IV dose 
of 300 mg BID-day1-then-QD and a higher dose of 400 mg BID-day1-then-QD, both had a 
zero probability achieving an AUC:MIC ratio of 167.  For a 500 mg BID-day1-then-QD 
regimen, PTA was 80%, and for the rest of the doses simulated (Figure 2) PTA was 100%. At 
the epidemiological cut-off point for Aspergillus species (MIC=0.5 mg/L) a very high dose of 
2000 mg BID-day1-then-QD was required to achieve mean AUC/MIC ratio of 175.1 ± 6.6, 
with a  90% PTA of achieving a value > 167. These findings are consistent with previous pre-
clinical reports (15). Therefore, the result of this case study shows the possibility of sub-
optimal exposure against less suceptible Aspergillus species with the currently approved IV 
dosing regimen in some cases of patients with marked hypoalbuminemia who are receiving 
CVVHDF. However, our patient exhibited distinctly low concentrations, and thus the 
predicted steady state exposures are unlikely to be extrapolable to the general critically ill 
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patient population. The results only show the likelihood in an isolated case such as the study 
patient. An important limitation of a PK analysis based on data from a single patient is that a 
representative model describing the PK of the study population is difficult to derive.  
In conclusion, this case study demonstrated that the currently approved IV posaconazole 
regimen achieved recommended total drug exposures for the treatment of susceptible yeast 
infections in a patient with marked hypalbuminaemia receiving CVVHDF. In addition, it 
confirmed previous findings (6, 7) that no supranormal posaconazole accumulation occurs 
following IV administration in a patient undergoing CVVHDF. Nor does altered hepatic 
function (ALT 66 and AST 162 IU/mL) result in accumulation. On the other hand, plasma 
concentrations could fall below therapeutic concentrations required for the treatment of 
invasive aspergillosis in isolated cases of patients with marked hypoalbuminemia such as the 
study patient.  
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Figure Legends  
Figure. 1. Observed total posaconazole concentration-time profile after a single intravenous 
dose of 300 mg. Circles indicate the observed data and solid represents the posterior 
predicted concentrations from the model. 
Figure 2. Monte-Carlo simulation predicted probability of target attainment for an AUC/MIC 
ratio of 167. Simulated dose were for twice daily dosing on day 1 followed by once daily 
dosing thereafter.   
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Figure 1  
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Figure 2  
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Table 1. Dosing simulations (n=1000) predicted average steady state exposure for various 
intravenous dosing regimens of posaconazole and the probability of achieving total trough 
concentration recommended for therapeutic effect in severely ill patients (> 1mg/L) and other 
patients (> 0.7 mg/L)  
Dosing regimen 
AUC0-24h at steady 
state from 120 h to 
144 h     (mean ± SD, 
mg/L*h) 
Probability (%) that 
steady-state total 
trough concentration  
at 164 h post dose is    
> 1mg/L > 0.7mg/L 
300 mg BID on day 1 and QD thereafter 13.1 ± 1.0 1 27 
400 mg BID on day 1 and QD thereafter 17.5 ± 1.1 13 73 
500 mg BID on day 1 and QD thereafter  21.9 ± 1.2 53 94 
750 mg BID on day 1 and QD thereafter 32.8 ± 1.6 98 100 
1000 mg BID on day 1 and QD thereafter 43.8 ± 1.9 100 100 
2000 mg BID on day 1 and QD thereafter 87.6 ± 3.3 100 100 
 
 
